在新药研发与创新的道路上,艾伯维公司再次为我们带来了令人振奋的消息。2025年5月14日,艾伯维不仅宣布了EMRELIS™(telisotuzumab vedotin-tllv)获得美国食品药品监督管理局(FDA)加速批准的好消息,还与ADARx制药公司达成了一项重要的合作及许可选择权协议,共同开发新一代siRNA疗法。这一天,对于艾伯维来说,是收获满满的一天;对于全球患者而言,更是充满希望的一天...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.